Alembic’s Aleor joint venture gets FDA green light for generic desonide
Alembic’s joint venture, Aleor Dermaceuticals, has received the Food and Drug Administration’s blessing for desonide ointment, 0.05%.
The product is the generic of Perrigo’s desonide ointment, 0.05%.
It is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Desonide ointment, 0.05%, had a market value of $13 million for the 12 months ended December 2018, according to IQVIA.